TLDR
- Shares of Palantir declined 2% to $131.94 during Tuesday’s session, marking a 26% decline in 2026 and sitting 36% below its November 2025 peak of $207.18.
- Wolfe Research elevated PLTR from Underperform to Peer Perform rating, though no specific price target was established.
- Analysts at Wolfe described Palantir as leading enterprise AI implementation while cautioning that its valuation is “the most expensive in software.”
- UBS continues with a Buy recommendation and $200 target despite mounting worries about rivals including OpenAI, Anthropic, and Databricks.
- Among 32 analysts monitored by FactSet, PLTR receives an average Overweight recommendation with a mean target of $189.87, suggesting 44% potential gains.
Palantir Technologies (PLTR) received favorable analyst attention from Wolfe Research on Tuesday. Shares declined anyway.
This market reaction speaks volumes about current investor psychology.
Palantir Technologies Inc., PLTR
Shares closed at $131.94 on Tuesday, continuing a challenging period that has erased 26% of value in 2026. June alone has witnessed a 16% retreat, while the stock trades 36% beneath its all-time closing peak of $207.18 achieved on November 3, 2025.
Meanwhile, the S&P 500 has climbed 10% this year, with the Nasdaq Composite advancing approximately 14%.
Analysts Alex Zukin and Joshua Tilton from Wolfe Research reinstated coverage of PLTR with a Peer Perform designation, representing an elevation from their previous Underperform stance. The firm opted not to issue a specific price objective.
Their assessment presents a mixed picture. While they recognize Palantir as the foremost enterprise AI software provider with industry-leading expansion rates, they emphasize that the stock’s present valuation “is still the most expensive in software.”
PLTR currently commands a forward price-to-earnings multiple of approximately 77.4 times, vastly exceeding the S&P 500’s 21.07 times.
“We love the business,” Zukin stated, “and if growth trends closer to our upside scenario we could find ourselves looking at an entry point too good to ignore.” However, the firm believes the present multiple already reflects much of the anticipated growth and profitability expansion.
Ontology Platform Takes Center Stage
The Wolfe analysts highlighted Palantir’s Ontology infrastructure as the crucial competitive advantage. This proprietary system integrates artificial intelligence with human judgment to streamline enterprise workflows. Zukin observed that Ontology revenue and pipeline are gaining momentum in 2026, representing an encouraging indicator.
Earlier in the day, UBS analyst Karl Keirstead confirmed his Buy rating alongside a $200 price objective. Keirstead maintained his optimistic outlook following discussions with Palantir leadership that centered extensively on competitive dynamics.
Competitive Landscape Under Scrutiny
The primary investor concern during the UBS engagement centered on whether competitors such as OpenAI, Anthropic, and Databricks — each developing field implementation capabilities and data infrastructure — might erode Palantir’s ontology advantage.
Palantir executives countered these concerns, emphasizing that their platform extends far beyond large language model deployment or data ingestion. Management expressed skepticism that LLM providers would achieve substantial traction in advancing into data layer functionality.
Palantir maintains an 84% gross profit margin, which UBS highlighted as proof of robust pricing authority and market position.
InvestingPro data indicates 21 analysts have recently increased their earnings projections.
Additional recent activity includes Rosenblatt confirming a Buy rating following client acquisitions and a Google Cloud collaboration unveiled at AIPCon 10. Baird similarly sustained an Outperform designation with a $200 target following separate investor discussions with Palantir executives.
The United Kingdom government disclosed plans to examine Palantir’s agreement with the National Health Service.
Across 32 firms monitored by FactSet, PLTR maintains an average Overweight recommendation with a collective price target of $189.87, indicating 44% prospective appreciation from present trading levels.
